Surveying the next 12 months, J&J expects to chart roughly 3% sales growth to $91.3 billion in 2025 by “overcoming headwinds associated with U.S. biosimilar ... about the Humira erosion curve ...

A few initial considerations outlined on this chart regarding the planned ... throughout the year as the number of biosimilar entrants increase. HUMIRA's erosion curve, once faced with material ...

Humira®, manufactured by AbbVie ... Biosimilars continue to gain influence. A comprehensive biosimilar chart featured in the Outlook includes 24 molecules with corresponding FDA-approved ...

Humira®, STELARA® (Janssen Biotech) and SKYRIZI® (AbbVie) are projected to have the largest price increases for the mentioned timeframe. Biosimilars continue to gain influence. A comprehensive ...

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also ...

Adalimumab biosimilar market share reached 23% in November 2024, a 1% increase since August. A majority of biosimilar gains are due to Hyrimoz (adalimumab-adaz) and Hadlima (adalimumab-bwwd).

AbbVie's cash-cow immunology product Humira has its first biosimilar competition in the US market with the launch of Amgen's copycat product Amjevita, several years after it was approved by the FDA.

CEO David Joyner highlighted the company's Q4 adjusted EPS of $1.19 and adjusted operating income of $2.7 billion. He introduced 2025 adjusted EPS guidance of $5.75 to $6.00, emphasizing recovery in ...